← Back to Screener
Cardiff Oncology, Inc. Common Stock (CRDF)
Price$1.78
Favorite Metrics
Price vs S&P 500 (26W)-27.30%
Price vs S&P 500 (4W)-9.49%
Market Capitalization$123.06M
All Metrics
Book Value / Share (Quarterly)$0.66
P/TBV (Annual)0.50x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)14.99%
Cash Flow / Share (Quarterly)$-0.56
Price vs S&P 500 (YTD)-40.08%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)-7732.04%
EPS (TTM)$-0.69
10-Day Avg Trading Volume0.90M
EPS Excl Extra (TTM)$-0.69
Revenue Growth (5Y)9.89%
EPS (Annual)$-0.69
ROI (Annual)-101.02%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-8131.43%
Cash / Share (Quarterly)$0.85
Revenue Growth QoQ (YoY)60.93%
ROA (Last FY)-74.09%
Revenue Growth TTM (YoY)-13.30%
EBITD / Share (TTM)$-0.73
ROE (5Y Avg)-54.35%
Operating Margin (TTM)-8256.32%
Cash Flow / Share (Annual)$-0.56
P/B Ratio2.71x
P/B Ratio (Quarterly)4.17x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)178.06x
Net Interest Coverage (TTM)-100.63x
ROA (TTM)-64.08%
EPS Incl Extra (Annual)$-0.69
Current Ratio (Annual)3.67x
Quick Ratio (Quarterly)3.57x
3-Month Avg Trading Volume1.08M
52-Week Price Return-35.94%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.74
P/S Ratio (Annual)207.52x
Asset Turnover (Annual)0.01x
52-Week High$4.55
Operating Margin (5Y Avg)-8586.53%
EPS Excl Extra (Annual)$-0.69
CapEx CAGR (5Y)-26.84%
Tangible BV CAGR (5Y)74.85%
26-Week Price Return-18.55%
Quick Ratio (Annual)3.59x
13-Week Price Return-35.94%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.67x
Enterprise Value$105.587
Revenue / Share Growth (5Y)-12.85%
Asset Turnover (TTM)0.01x
Book Value / Share Growth (5Y)-28.19%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-7732.04%
Cash / Share (Annual)$0.85
3-Month Return Std Dev96.02%
Gross Margin (5Y Avg)-134.65%
Net Income / Employee (TTM)$-1
ROE (Last FY)-101.02%
Net Interest Coverage (Annual)-65.17x
EPS Basic Excl Extra (Annual)$-0.69
Receivables Turnover (TTM)1.24x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.69
Receivables Turnover (Annual)0.72x
ROI (TTM)-82.00%
P/S Ratio (TTM)207.52x
Pretax Margin (5Y Avg)-8131.43%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$2.38
Price vs S&P 500 (52W)-71.04%
Year-to-Date Return-35.94%
5-Day Price Return13.21%
EPS Normalized (Annual)$-0.69
ROA (5Y Avg)-44.76%
Net Profit Margin (Annual)-7732.04%
Month-to-Date Return11.11%
Cash Flow / Share (TTM)$-0.91
EBITD / Share (Annual)$-0.73
Operating Margin (Annual)-8256.32%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-54.35%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$-0.69
P/TBV (Quarterly)0.68x
P/B Ratio (Annual)4.17x
Pretax Margin (TTM)-7732.04%
Book Value / Share (Annual)$0.66
Price vs S&P 500 (13W)-38.81%
Beta1.37x
Revenue / Share (TTM)$0.01
ROE (TTM)-82.00%
52-Week Low$1.48
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.13
4.07
4.07
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CRDFCardiff Oncology, Inc. Common Stock | 207.52x | -13.30% | 100.00% | — | $1.78 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Cardiff Oncology is a clinical-stage biotechnology company developing onvansertib, an oral PLK1 inhibitor designed to enhance standard cancer treatments through combination therapy. The company is advancing clinical trials in RAS-mutated metastatic colorectal cancer, pancreatic cancer, small cell lung cancer, triple negative breast cancer, and chronic myelomonocytic leukemia.